Valeant Pharmaceuticals

GSK, Valeant strike deal on epilepsy drug

News & Observer (Free subscription) | yesterday

GlaxoSmithKline will pay Valeant Pharmaceuticals International as much as $820 million and a share of profit from the experimental epilepsy drug retigabine.

Glaxo, Valeant Agree to Drug Deal

Law Blog - WSJ.com (Free subscription) | 28/08/2008

GlaxoSmithKline is teaming up with Valeant Pharmaceuticals to develop an experimental epilepsy drug, retigabine, in a deal whose value could reach $820 million.

Valeant Pharmaceuticals and GlaxoSmithKline Announce Worldwide Collaboration Agreement for Retigabine

Business Wire (Free subscription) | 28/08/2008

ALISO VIEJO, Calif. & LONDON--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) and GlaxoSmithKline (GSK) today announced that they have entered into an exclusive worldwide

• Valeant, GlaxoSmithKline sign collaboration deal for epilepsy drug - The Los Angeles Business
• GSK signs $820M drug development deal - The Triangle Business Journal
• See the 5 articles on the same subject

Valeant Pharmaceuticals to Present at UBS Global Life Sciences Conference

Business Wire (Free subscription) | 22/08/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE: VRX) today announced that members of its senior management team will make a presentation at the UBS Global

Valeant Pharmaceuticals International Q2 2008 Earnings Call Transcript

Seeking Alpha (Free subscription) | 11/08/2008

Valeant Pharmaceuticals International (VRX) Q2 2008 Earnings Call Transcript Complete Story »

Valeant swings to loss in 2Q

The Los Angeles Business (Free subscription) | 11/08/2008

Lower sales and higher taxes pushed Valeant Pharmaceuticals International to a loss for the second quarter, the company said Monday. (VRX)

Valeant Pharmaceuticals Reports Second Quarter Financial Results

Business Wire (Free subscription) | 11/08/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced second quarter financial results for 2008.

Valeant, Meda Form JV

Contract Pharma Breaking News (Free subscription) | 07/08/2008

Valeant Pharmaceuticals and Meda AB have agreed to form joint ventures in Australia, Canada and Mexico to develop, market and commercialize certain current and future products. The joint ventures will be majority-owned by Meda; Valeant will own a minority interest. The joint ventures will initially include insomnia drug Sublinox and pain drug flupertine, with the option to include additional products...

• Meda Enters into Joint Venture with Valeant - Business Wire
• Valeant Announces Agreement to Enter into Joint Venture with Meda - Business Wire

Valeant Sells Certain Business Operations in Europe for $392 Million

The Earth Times Online Newspaper (Free subscription) | 04/08/2008

ALISO VIEJO, Calif. - Valeant Pharmaceuticals International (NYSE:VRX) announced today that it had agreed to sell its business operations located in Western Europe, Eastern Europe including Russia, and certain export markets to Meda AB, an international specialty pharmaceutical company locat

Valeant Sells Certain Business Operations in Europe for $392 Million

Business Wire (Free subscription) | 04/08/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) announced today that it had agreed to sell its business operations located in Western Europe, Eastern

Valeant Pharmaceuticals to Announce 2008 Second Quarter Results on August 11, 2008

Business Wire (Free subscription) | 21/07/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call on Monday, August 11, 2008 at 11:00 a.m. EDT (8:00

Valeant Announces Redemption of All Outstanding 7% Senior Notes Due 2011

Business Wire (Free subscription) | 20/06/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will redeem all of the $300 million aggregate principal amount outstanding of

Valeant Pharmaceuticals Announces Increase in Share Repurchase Authorization

The Earth Times Online Newspaper (Free subscription) | 17/06/2008

ALISO VIEJO, Calif. - Valeant Pharmaceuticals International (NYSE: VRX) today announced that its board of directors has authorized the repurchase of an additional $100 million of its outstanding common stock under its 2007 stock repurchase program. This repurchase authorization raises the ag

Valeant Pharmaceuticals Announces Increase in Share Repurchase Authorization

Business Wire (Free subscription) | 17/06/2008

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE: VRX) today announced that its board of directors has authorized the repurchase of an additional $100

Valeant Pharmaceuticals divests Argentina operations

Market Watch (Free subscription) | 10/06/2008

NEW YORK (MarketWatch) -- Valeant Pharmaceuticals International said Tuesday it has divested its commercial operations in Argentina to an unnamed Argentinean pharmaceutical company. Financial terms were not disclosed. "One of our strategic initiatives for 2008 is to divest certain regions and simplify our operations," Chairman and CEO Michael Pearson said in the statement announcing the move. Market...